Insider Selling: Alnylam Pharmaceuticals, Inc. (ALNY) EVP Sells $825,000.00 in Stock

Insider Selling: Alnylam Pharmaceuticals, Inc. (ALNY) EVP Sells $825,000.00 in Stock

Akshay Vaishnaw also recently made the following trade(s):

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Akshay Vaishnaw sold 11,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares of the company’s stock, valued at $1,597,275. The sale was disclosed in a document filed with the SEC, which is available through this link.

Alnylam Pharmaceuticals, Inc. (ALNY) opened at 65.80 on Tuesday. The firm’s market cap is $5.67 billion. The company’s 50 day moving average is $57.45 and its 200 day moving average is $48.37. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $80.11.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The firm had revenue of $19 million for the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 37.25% and a negative net margin of 869.63%. Alnylam Pharmaceuticals’s quarterly revenue was up 160.3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.21) earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.34) earnings per share for the current year.

ALNY has been the subject of a number of recent research reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 2nd. They set a “buy” rating and a $75.00 price objective for the company. JMP Securities set a $69.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 3rd. Vetr cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $46.77 target price for the company. in a research note on Monday, February 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $68.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 9th. Finally, FBR & Co reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $70.87.

Several hedge funds have recently bought and sold shares of ALNY. PNC Financial Services Group Inc. increased its stake in Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 36 shares in the last quarter. Hsbc Holdings PLC increased its stake in Alnylam Pharmaceuticals by 1.5% in the third quarter. Hsbc Holdings PLC now owns 10,047 shares of the biopharmaceutical company’s stock valued at $681,000 after buying an additional 151 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares in the last quarter. Swiss National Bank increased its stake in Alnylam Pharmaceuticals by 0.6% in the first quarter. Swiss National Bank now owns 127,700 shares of the biopharmaceutical company’s stock valued at $6,545,000 after buying an additional 800 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in Alnylam Pharmaceuticals by 19.4% in the first quarter. Pacer Advisors Inc. now owns 9,517 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 1,544 shares in the last quarter. 88.70% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ALNY”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment